Improvements in self‐confidence and satisfaction with self‐injection after introducing self‐injection of dupilumab in patients with atopic dermatitis
Abstract Dupilumab was approved for treating adult patients with atopic dermatitis (AD) refractory to topical therapy in Japan in April 2018, and self‐injection of dupilumab has been available since May 2019. Subcutaneous self‐injection of medication has benefits for patients and the healthcare syst...
保存先:
| 主要な著者: | , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2023-10-01
|
| シリーズ: | Journal of Cutaneous Immunology and Allergy |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1002/cia2.12313 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|